5-alkyl-6-[[amino]methyl]pyrido[2,3-D]pyrimidine derivatives and methods of using these derivatives

A method of therapeutically treating a patient for an illness consisting of employing a compound and a pharmaceutically acceptable salt thereof having the formula:

• ##STR5## wherein x and y are the same or different and are selected from the group consisting of OH and NH.sub.2 ;
• wherein R.sub.1 is selected from the group consisting of hydrogen, a first lower alkyl group, a nitroso group and a formyl group and wherein R.sub.2 is selected from the group consisting of a second lower alkyl group which is the same as or different than said first lower alkyl group, an aryl group, an alkylaryl group, and each substituent of said substituted aryl group or said substituted alkylaryl group is the same as or selected from the group consisting of a third lower alkyl group which is the same as or different than said first lower alkyl group or said second lower alkyl group, an alkoxy group, a substituted alkoxyaryloxy group and a halogen, wherein R.sub.3 is a fourth lower alkyl group which is the same as or different than said first lower alkyl group, said second lower alkyl group or said third lower alkyl group;
• incorporating said compound in a suitable pharmaceutical carrier,
• administering a therapeutically effective amount of said compound incorporated in said carrier to a patient;
• and
• employing said method in prophylactically treating a patient to provide protection against an illness selected from the group consisting of Pneumocystis carinii and Toxoplasmosis gondii.

A method consisting of prophylactically administering to a patient a compound and a pharmaceutically acceptable salt thereof having the formula:

• ##STR6## wherein x and y are the same or different and are selected from the group consisting of OH and HN.sub.2 ;
• wherein R.sub.1 is selected from the group consisting of hydrogen, a first lower alkyl group, a nitroso group and a formyl group and wherein R.sub.2 is selected from the group consisting of a second lower alkyl group which is the same as or different than said first lower alkyl group, an aryl group, an alkylaryl group, and each substituent of said substituted aryl group or said substituted alkylaryl group is the same or different and is selected from the group consisting of a third lower alkyl group which is the same as or different than said first lower alkyl group or said second lower alkyl group, an alkoxy group, a substituted alkoxyaryloxy group and a halogen, wherein R.sub.3 is a fourth lower alkyl group which is the same as or different than said first lower alkyl group, said second lower alkyl group or said third lower alkyl group;
• incorporating said compound in a suitable pharmaceutical carrier,
• administering a prophylactically effective amount of said compound incorporated in said carrier to a patient who is immunocompromised;
• and
• employing said method in prophylactically treating a patient to provide protection against an illness selected from the group consisting of Pneumocystis carinii and Toxoplasmosis gondii.